Syntax Research, Inc. Regeneron Pharmaceuticals, Inc. Transaction History
Syntax Research, Inc.
- $131 Billion
- Q1 2024
A detailed history of Syntax Research, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Syntax Research, Inc. holds 345 shares of REGN stock, worth $356,809. This represents 0.25% of its overall portfolio holdings.
Number of Shares
345
Previous 345
-0.0%
Holding current value
$356,809
Previous $303 Million
9.59%
% of portfolio
0.25%
Previous 0.25%
Shares
1 transactions
Others Institutions Holding REGN
# of Institutions
1,427Shares Held
82.1MCall Options Held
835KPut Options Held
1.46M-
Vanguard Group Inc Valley Forge, PA8.93MShares$9.24 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$8.86 Billion0.19% of portfolio
-
Jpmorgan Chase & CO New York, NY7.73MShares$7.99 Billion0.68% of portfolio
-
State Street Corp Boston, MA4.84MShares$5.01 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.65MShares$4.81 Billion0.76% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $111B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...